About Us
Our Story
Team
Careers
News
Partner with us
Forgot password?
Sign in
Login
Login
Email
Password
Forgot your password?
Join VuMedi
Select specialty
Select specialty
Adult & Family Medicine
Allergy, Asthma, Immunology
Anesthesiology
Cardiovascular
Dental
Dermatology
Emergency Medicine
Endocrinology
Gastroenterology & Hepatology
General Surgery
Hematology & Oncology
Infectious Disease
Medical Genetics
Nephrology
Neurology
Neurosurgery
Obstetrics/Gynecology
Ophthalmology
Oral Maxillofacial
Orthopaedics
Otolaryngology
Pathology
Pediatrics
Physical Medicine & Rehab
Plastic Surgery
Podiatry
Preventive Medicine
Psychiatry
Pulmonology
Radiation Oncology
Radiology
Rheumatology
Urology
First name
Last name
Email
Choose Password
Confirm Password
Updates to Management of Patients With Multiple Myeloma
By
Total Health
FEATURING
Shaji Kumar
October 20, 2022
0 Comments
Login to view comments.
Click here to Login
Related Content
AUTOPLAY
ON
Dana-Farber Cancer Institute
Dana-Farber Cancer Institute's ASH Highlights
Sat, Feb 11, 2023
12:38
SOHO 2022 Tenth Annual Meeting
SOHO 2022 DEBATE: Bispecific Antibodies vs. CAR-T for R/R MM - Defen…
Feat.
S. Usmani
04:08
CancerGRACE
CAR T-Cell Therapy Side Effects for Blood Cancers
Feat.
A. Goodman
05:56
ASH 2022 Conference Coverage
ASH 2022 Myeloma XI Trial: Defining the Optimal Duration of Lenalido…
Feat.
G. Morgan
15:54
Paul Richardson
Emerging Strategies in the Management of Relapsed MM
30:59
Houston Methodist Hospital
Overview of Advances in Multiple Myeloma
Feat.
S. Ganguly
09:09
Douglas W. Sborov
IMS 2022 Final Analysis of the GRIFFIN Trial: Daratumumab + Lenalido…
21:38
Rahul Banerjee
CAR-T Therapy in Myeloma: What's Here and What's Coming So…
04:31
ASH 2022 Conference Coverage
ASH 2022 GRIFFIN Trial Final Analysis: D-RVd in Clinically Relevant …
Feat.
A. Chari
06:41
Hamza Hashmi
Idecabtagene Vicleucel vs. Ciltacabtagene Autoleucel: A Sophie'…
21:16
UChicago Medicine
Myeloma 2022: Challenges and Path Forward
Feat.
A. Jakubowiak
34:48
Kenneth Anderson
MM Cured in 2030 - What Are the Next Steps?
Feat.
K. Anderson
10:09
SOHO 2022 Tenth Annual Meeting
SOHO 2022: Next Questions for MM in the Coming 5-10 Years
Feat.
T. Martin
24:19
Dana-Farber Cancer Institute
Phase 3 DETERMINATION Trial: RVd ± ASCT & Lenalidomide Maintenan…
Feat.
P. Richardson
45:43
MedNews Week
Multiple Myeloma in 2022: Developments, Directions, and Disparities
Feat.
J. Mikhael
34:28
2022 Community Oncology Conference
Treatment Conundrums in Myeloma
Feat.
S. Giralt
13:46
SOHO 2022 Tenth Annual Meeting
SOHO 2022: Bispecific T-Cell Engagers - Early Data and Where Will We…
Feat.
R. Orlowski
33:28
Cleveland Clinic Taussig Cancer Institute
Management of Relapsed/Refractory Multiple Myeloma
Feat.
F. Anwer
10:08
ASH 2022 Conference Coverage
ASH 2022 Maintenance Therapy Cessation for Sustained MRD Negative MM…
Feat.
N. Korde
06:58
Saurabh Chhabra
Summary of the MAMMOTH Trial in R/R Myeloma
10:34
SOHO 2022 Tenth Annual Meeting
SOHO 2022 Next Questions: Cellular Therapy
Feat.
K. Komanduri
